JB Pharma Q3 FY26 Profit Jumps 22% to Rs 198 Crore on Strong Domestic, International Growth

Operating EBITDA margin improved to 28.7 per cent during the quarter, up from 28.1 per cent a year ago, supported by favourable product mix, cost optimisation initiatives and operational efficiencies.

Commenting on the results, Nikhil Chopra, CEO and Whole-Time Director, JB Pharma, said the company’s domestic formulations business continued to outperform the Indian pharmaceutical market, led by broad-based growth across key chronic therapies and sustained strength in flagship brands. He added that the CDMO business maintained positive momentum, while international formulations recorded strong growth in several key markets.

“Improved operating margins in Q3 FY26 and 9M FY26 reflect our continued focus on cost optimisation and operational excellence. With a strong balance sheet and net cash position, we remain confident of delivering profitable growth going forward,” Chopra said.

Nine-month performance

For the nine months ended December 31, 2025 (9M FY26), JB Pharma reported revenue of ₹3,244 crore, up 9 per cent from ₹2,969 crore in the same period last year. Operating EBITDA increased 13 per cent to ₹955 crore, while profit after tax rose 18 per cent to ₹608 crore. EBITDA margin for the nine-month period improved to 29.4 per cent compared to 28.5 per cent in 9M FY25.

Business segment performance

In Q3 FY26, the domestic formulations business recorded revenue of ₹620 crore, registering 10 per cent year-on-year growth and accounting for 60 per cent of overall turnover in the nine-month period. As per IQVIA MAT December 2025 data, JB Pharma outperformed the Indian Pharmaceutical Market (IPM), clocking growth of 12 per cent versus IPM growth of 9 per cent. Key brands such as Cilacar, Cilacar-T, Nicardia and Sporlac continued to post strong growth, while the Razel franchise grew 11 per cent year-on-year to ₹108 crore.

International business revenue increased 12 per cent year-on-year to ₹445 crore in Q3 FY26. International formulations grew 20 per cent to ₹306 crore, with strong performance across South Africa, Russia, the US and branded exports markets. The CDMO business remained nearly flat at ₹117 crore during the quarter, though the company said sales momentum is expected to continue into Q4 FY26.

Gross margins improved to 69.1 per cent in Q3 FY26, an expansion of 200 basis points over the year-ago quarter, aided by better product mix, stable raw material prices and positive pricing trends. Other income rose to ₹18 crore during the quarter, primarily due to treasury income.

JB Pharma said domestic and CDMO businesses together accounted for nearly 70 per cent of overall revenue in the nine-month period, underscoring the resilience of its core operations.

JB Chemicals & Pharmaceuticals Ltd, established in 1976, is among India’s fastest-growing pharmaceutical companies and a leading player in the hypertension segment, with a strong presence in India, Russia and South Africa, and exports to over 40 countries.